Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Clasificación en acciones
#3422
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Precio por acción
$4.48
Capitalización bursátil
$4.99B
Cambio (1 día)
-5.20%
Cambio (1 año)
-41.89%
País
CN
Comercio Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Categoría
Healthcare
Ratio P/S de Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Ratio P/S al October 2026 TTM: 7.09
Según los informes financieros más recientes y el precio de las acciones de Shenzhen Salubris Pharmaceuticals Co., Ltd., el ratio P/S actual (TTM) es 7.09. Al final de 2024, el ratio P/S era 8.59.
Historial del ratio P/S de Shenzhen Salubris Pharmaceuticals Co., Ltd. desde 2006 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2026 (TTM) | 7.09 | -44.73% |
| 2025 | 12.83 | 49.35% |
| 2024 | 8.59 | -20.58% |
| 2023 | 10.81 | 4.34% |
| 2022 | 10.36 | 8.68% |
| 2021 | 9.54 | -10.38% |
| 2020 | 10.64 | 128.80% |
| 2019 | 4.65 | 6.64% |
| 2018 | 4.36 | -57.85% |
| 2017 | 10.35 | 29.67% |
| 2016 | 7.98 | -11.93% |
| 2015 | 9.06 | 13.07% |
| 2014 | 8.01 | -17.09% |
| 2013 | 9.66 | 5.70% |
| 2012 | 9.14 | 53.31% |
| 2011 | 5.96 | -52.70% |
| 2010 | 12.61 | 30.91% |
| 2009 | 9.63 | -9.70% |
| 2008 | 10.67 | -33.95% |
| 2007 | 16.15 | -30.69% |
| 2006 | 23.30 | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 13.24 | 86.77% |
US
|
|
| 2.74 | -61.33% |
FR
|
|
| 8.98 | 26.59% |
JP
|
|
| 2.54 | -64.18% |
US
|
|
| 3.02 | -57.47% |
CH
|
